{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:46:41Z","timestamp":1786996001831,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.psychres.2016.01.018","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T21:31:23Z","timestamp":1452288683000},"page":"179-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Serum soluble urokinase-type plasminogen activator receptor levels in male patients with acute exacerbation of schizophrenia"],"prefix":"10.1016","volume":"236","author":[{"given":"Abdullah","family":"Genc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tevfik","family":"Kalelioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrin","family":"Karamustafalioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akif","family":"Tasdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra Sena","family":"Genc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Akkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Emul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2016.01.018_bib1","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2147\/NDT.S50006","article-title":"Etiology of cardiovascular disease in patients with schizophrenia: current perspectives","volume":"11","author":"Emul","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"8","key":"10.1016\/j.psychres.2016.01.018_bib2","first-page":"686","article-title":"The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau","volume":"6","author":"Eugen-Olsen","year":"2002","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"3","key":"10.1016\/j.psychres.2016.01.018_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2796.2010.02252.x","article-title":"Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population","volume":"268","author":"Eugen-Olsen","year":"2010","journal-title":"J. Intern. Med."},{"issue":"9","key":"10.1016\/j.psychres.2016.01.018_bib4","first-page":"10","article-title":"Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants","volume":"20","author":"Haastrup","year":"2014","journal-title":"Plos One"},{"key":"10.1016\/j.psychres.2016.01.018_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.mp.4001558","article-title":"Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence","volume":"10","author":"Harrison","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.018_bib6","first-page":"91","article-title":"Risk factors associated with serum levels of the Inflammatory Biomarker Soluble Urokinase Plasminogen Activator","volume":"9","author":"Haupt","year":"2014","journal-title":"Recept. a Gen. Popul. Biomark. Insights"},{"key":"10.1016\/j.psychres.2016.01.018_bib7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/jamapsychiatry.2014.1332","article-title":"Association of serum interleukin-6 and c-reactive protein in childhood with depression and psychosis in young adult life: a population based longitudinal study","volume":"71","author":"Khandaker","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2016.01.018_bib8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ijcard.2012.03.040","article-title":"CRP and suPAR are differently related to anthropometry and subclinical organ damage","volume":"167","author":"Lyngbaek","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.psychres.2016.01.018_bib9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2016.01.018_bib10","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/schbul\/sbu118","article-title":"Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia","volume":"41","author":"Nielsen","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.psychres.2016.01.018_bib11","first-page":"18","article-title":"Effects of risperidone on cytokine profile in drug-na\u00efve first-episode psychosis","volume":"31","author":"Noto","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2016.01.018_bib12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.psychres.2007.11.014","article-title":"Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia","volume":"160","author":"O\u2019Brien","year":"2008","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.psychres.2016.01.018_bib13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.atherosclerosis.2011.10.039","article-title":"Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malm\u00f6 Diet and Cancer Study","volume":"220","author":"Persson","year":"2012","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.psychres.2016.01.018_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.9758\/cpn.2013.11.3.107","article-title":"The neuroimmunology of schizophrenia","volume":"11","author":"Smyth","year":"2013","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.psychres.2016.01.018_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1155\/2009\/504294","article-title":"suPAR: the molecular crystal ball","volume":"27","author":"Thuno","year":"2009","journal-title":"Dis. Markers"},{"key":"10.1016\/j.psychres.2016.01.018_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","article-title":"Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis","volume":"155","author":"Upthegrove","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2016.01.018_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1469-0691.2004.00850.x","article-title":"The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality","volume":"10","author":"Wittenhagen","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.psychres.2016.01.018_bib18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00415-010-5788-9","article-title":"Disease-relevant autoantibodies in first episode schizophrenia","volume":"258","author":"Zandi","year":"2011","journal-title":"J. Neurol."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178115301062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178115301062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T01:45:55Z","timestamp":1572659155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178115301062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":18,"alternative-id":["S0165178115301062"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2016.01.018","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum soluble urokinase-type plasminogen activator receptor levels in male patients with acute exacerbation of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2016.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}